English

Talis Biomedical Corporation

EDGAR

TLIS Quarterly report (10-Q) · filed 2024-08-19

18 filing records in this dataset, filed from 2021-01-22 to 2024-08-19. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2024 Q2 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-11.3 million USD

2024 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -17757000 USD Source
Operating Cash Flow: -6427000 USD Source

Free cash flow

-11.3 million USD

2024 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -17757000 USD Source
Operating Cash Flow: -6427000 USD Source
Capital Expenditure: 0 USD Source
Capital Expenditure: 0 USD Source

Cash and cash equivalents: 59.9 million USD 2024-06-30 Source
Exact value

59900000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 1.82 million shares 2024-06-30 Source
Exact value

1822153 shares

Reported share-count change

0.17% · 3.12 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

1819029 shares · 2023-06-30· Source
1822153 shares · 2024-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

408 thousand USD

2023-07-01 – 2024-06-30

Exact inputs and evidence

Revenue: 140000 USD · 2023-07-01 – 2023-09-30 Source
Revenue: 2134000 USD · 2023-01-01 – 2023-12-31 Source
Revenue: 1939000 USD · 2023-01-01 – 2023-09-30 Source
Revenue: 73000 USD · 2024-01-01 – 2024-03-31 Source
Revenue: 0 USD · 2024-04-01 – 2024-06-30 Source

Net income

-51 million USD

2023-07-01 – 2024-06-30

Exact inputs and evidence

Net income: -15682000 USD · 2023-07-01 – 2023-09-30 Source
Net income: -62007000 USD · 2023-01-01 – 2023-12-31 Source
Net income: -48547000 USD · 2023-01-01 – 2023-09-30 Source
Net income: -13035000 USD · 2024-01-01 – 2024-03-31 Source
Net income: -8849000 USD · 2024-04-01 – 2024-06-30 Source

Operating cash flow

-40.3 million USD

2023-07-01 – 2024-06-30

Exact inputs and evidence

Operating cash flow: -41883000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -30739000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -53240000 USD · 2023-01-01 – 2023-12-31 Source
Operating cash flow: -41883000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -6427000 USD · 2024-01-01 – 2024-03-31 Source
Operating cash flow: -17757000 USD · 2024-01-01 – 2024-06-30 Source
Operating cash flow: -6427000 USD · 2024-01-01 – 2024-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-08-19.

Financial data available through: 2023-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2023-12-31
Operating income: 4 of 11 periods available· newest 2023-12-31
Net income: 4 of 11 periods available· newest 2023-12-31
Operating cash flow: 4 of 11 periods available· newest 2023-12-31
Capital expenditure: 4 of 11 periods available· newest 2023-12-31
Total assets: 3 of 11 periods available· newest 2023-12-31
Total liabilities: 3 of 11 periods available· newest 2023-12-31
Current assets: 3 of 11 periods available· newest 2023-12-31
Current liabilities: 3 of 11 periods available· newest 2023-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2023-12-31
long term debt: No compatible figures in this window
Shares outstanding: 3 of 11 periods available· newest 2023-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-55.7%

Prior period

USD 4.81 million

2022-01-01 – 2022-12-31
Current period

USD 2.13 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

2134000 − 4812000 = -2678000 USD

4812000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
2134000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Talis Biomedical Corporation · 2023-12-31 Talis Biomedical Corporation (edgar:1584751) Year-over-year change in Revenue: -2678000 USD Concept: fundies:Revenue Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-08T15:32:14Z Snapshot: 76359e99ea5544dae0b145f58c9198a64d6485e398959fd41d681c608509871d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1584751?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 2134000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017024037648/tlis-20231231.htm#1072439 Filing: 000095017024037648 Input fundies:Revenue: 4812000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017024037648/tlis-20231231.htm#1073724 Filing: 000095017024037648
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 51.01 million

Prior period

−USD 113.01 million

2022-01-01 – 2022-12-31
Current period

−USD 62.01 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-62007000 − -113012000 = 51005000 USD

-113012000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-62007000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Talis Biomedical Corporation · 2023-12-31 Talis Biomedical Corporation (edgar:1584751) Year-over-year change in Net income: 51005000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-08T15:32:14Z Snapshot: 76359e99ea5544dae0b145f58c9198a64d6485e398959fd41d681c608509871d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1584751?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -62007000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017024037648/tlis-20231231.htm#1846739 Filing: 000095017024037648 Input fundies:NetIncome: -113012000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017024037648/tlis-20231231.htm#1848040 Filing: 000095017024037648
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 46.9 million

Prior period

−USD 100.14 million

2022-01-01 – 2022-12-31
Current period

−USD 53.24 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-53240000 − -100136000 = 46896000 USD

-100136000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-53240000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Talis Biomedical Corporation · 2023-12-31 Talis Biomedical Corporation (edgar:1584751) Year-over-year change in Operating cash flow: 46896000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-08T15:32:14Z Snapshot: 76359e99ea5544dae0b145f58c9198a64d6485e398959fd41d681c608509871d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1584751?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -53240000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017024037648/tlis-20231231.htm#1254568 Filing: 000095017024037648 Input fundies:OperatingCashFlow: -100136000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017024037648/tlis-20231231.htm#1256011 Filing: 000095017024037648
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-69.9%

Prior period

USD 1.62 million

2022-01-01 – 2022-12-31
Current period

USD 486,000

2023-01-01 – 2023-12-31

Exact inputs and evidence

486000 − 1615000 = -1129000 USD

1615000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
486000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Talis Biomedical Corporation · 2023-12-31 Talis Biomedical Corporation (edgar:1584751) Year-over-year change in Capital expenditure: -1129000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-08T15:32:14Z Snapshot: 76359e99ea5544dae0b145f58c9198a64d6485e398959fd41d681c608509871d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1584751?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 486000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017024037648/tlis-20231231.htm#1259640 Filing: 000095017024037648 Input fundies:CapitalExpenditure: 1615000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017024037648/tlis-20231231.htm#1261062 Filing: 000095017024037648
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2023-01-01 – 2023-12-31

Revenue USD 2.13 million 100% of revenue
Cost of revenue USD 41,000 1.9% of revenue
Operating expenses USD 68.91 million 3,229% of revenue
Operating income −USD 66.82 million −3,131% of revenue
Tax, interest and other Derived −USD 4.81 million −225% of revenue
Net income −USD 62.01 million −2,906% of revenue

Cash

Operating cash flow −USD 53.24 million −2,495% of revenue
Capital expenditure USD 486,000 23% of revenue
Free cash flow Derived −USD 53.73 million −2,518% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2021 Operating loss: operating costs were 2,441% of revenue.
2022 Operating loss: operating costs were 2,493% of revenue.
2023 Operating loss: operating costs were 3,231% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2021 2021-01-01 – 2021-12-31	8193000	200009000 Derived	-191816000	220000 Derived	-192036000	-174250000 Derived	Source 2021-01-01 – 2021-12-31: 8193000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -191816000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -192036000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -171384000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 2866000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	4812000	119951000 Derived	-115139000	-2127000 Derived	-113012000	-101751000 Derived	Source 2022-01-01 – 2022-12-31: 4812000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -115139000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -113012000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -100136000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 1615000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	2134000	68949000 Derived	-66815000	-4808000 Derived	-62007000	-53726000 Derived	Source 2023-01-01 – 2023-12-31: 2134000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -66815000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -62007000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -53240000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 486000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 2.1M 2023

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Revenue	8193000	Revenue: 8193000 Open source
20222022-12-31	Revenue	4812000	Revenue: 4812000 Open source
20232023-12-31	Revenue	2134000	Revenue: 2134000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-55.7% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Year over year	No prior comparable period	Revenue: 8193000 Open source
20222022-12-31	Year over year	-41.3%	Revenue: 4812000 Open source Revenue: 8193000 Open source
20232023-12-31	Year over year	-55.7%	Revenue: 2134000 Open source Revenue: 4812000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -3,131% 2023

Net margin -2,905.7% 2023

Free cash flow margin -2,517.6% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Operating margin	-2,341.2%	Operating Income: -191816000 Open source Revenue: 8193000 Open source
20222022-12-31	Operating margin	-2,392.7%	Operating Income: -115139000 Open source Revenue: 4812000 Open source
20232023-12-31	Operating margin	-3,131%	Operating Income: -66815000 Open source Revenue: 2134000 Open source
20212021-12-31	Net margin	-2,343.9%	Net Income: -192036000 Open source Revenue: 8193000 Open source
20222022-12-31	Net margin	-2,348.5%	Net Income: -113012000 Open source Revenue: 4812000 Open source
20232023-12-31	Net margin	-2,905.7%	Net Income: -62007000 Open source Revenue: 2134000 Open source
20212021-12-31	Free cash flow margin	-2,126.8%	Revenue: 8193000 Open source Operating Cash Flow: -171384000 Open source Capital Expenditure: 2866000 Open source
20222022-12-31	Free cash flow margin	-2,114.5%	Revenue: 4812000 Open source Operating Cash Flow: -100136000 Open source Capital Expenditure: 1615000 Open source
20232023-12-31	Free cash flow margin	-2,517.6%	Revenue: 2134000 Open source Operating Cash Flow: -53240000 Open source Capital Expenditure: 486000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -53.2M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Operating cash flow	-171384000	Operating Cash Flow: -171384000 Open source
20222022-12-31	Operating cash flow	-100136000	Operating Cash Flow: -100136000 Open source
20232023-12-31	Operating cash flow	-53240000	Operating Cash Flow: -53240000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -53.7M 2023

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Free cash flow	-174250000	Operating Cash Flow: -171384000 Open source Capital Expenditure: 2866000 Open source
20222022-12-31	Free cash flow	-101751000	Operating Cash Flow: -100136000 Open source Capital Expenditure: 1615000 Open source
20232023-12-31	Free cash flow	-53726000	Operating Cash Flow: -53240000 Open source Capital Expenditure: 486000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

27% 2023

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Liabilities / assets	12%	Total Liabilities: 31851000 Open source Total Assets: 265828000 Open source
20222022-12-31	Liabilities / assets	25.1%	Total Liabilities: 42551000 Open source Total Assets: 169290000 Open source
20232023-12-31	Liabilities / assets	27%	Total Liabilities: 25558000 Open source Total Assets: 94674000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

8.86× 2023

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Current assets / current liabilities	12.36×	Current Assets: 236115000 Open source Current Liabilities: 19106000 Open source
20222022-12-31	Current assets / current liabilities	10.52×	Current Assets: 133282000 Open source Current Liabilities: 12672000 Open source
20232023-12-31	Current assets / current liabilities	8.86×	Current Assets: 77683000 Open source Current Liabilities: 8772000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	−USD 91.13 million Exact value Exact value: -91130000 USD 2020-01-01 – 2020-12-31: -91130000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Talis Biomedical Corporation · 2020-12-31 Talis Biomedical Corporation (edgar:1584751) Net Income: -91130000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-08T15:32:14Z Snapshot: 76359e99ea5544dae0b145f58c9198a64d6485e398959fd41d681c608509871d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1584751/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -91130000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017022003779/tlis-20211231.htm#2896433 Filing: 000095017022003779 The citation records this snapshot. The page link may show a newer release later.	−USD 87.02 million Exact value Exact value: -87024000 USD 2020-01-01 – 2020-12-31: -87024000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Talis Biomedical Corporation · 2020-12-31 Talis Biomedical Corporation (edgar:1584751) Operating Cash Flow: -87024000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-08T15:32:14Z Snapshot: 76359e99ea5544dae0b145f58c9198a64d6485e398959fd41d681c608509871d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1584751/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -87024000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017022003779/tlis-20211231.htm#1854615 Filing: 000095017022003779 The citation records this snapshot. The page link may show a newer release later.	USD 8.2 million Exact value Exact value: 8201000 USD 2020-01-01 – 2020-12-31: 8201000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Talis Biomedical Corporation · 2020-12-31 Talis Biomedical Corporation (edgar:1584751) Capital Expenditure: 8201000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-08T15:32:14Z Snapshot: 76359e99ea5544dae0b145f58c9198a64d6485e398959fd41d681c608509871d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1584751/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8201000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017022003779/tlis-20211231.htm#1862023 Filing: 000095017022003779 The citation records this snapshot. The page link may show a newer release later.	−USD 95.23 million Calculation and evidence -87024000 − 8201000 USD Exact free cash flow: -95225000 USD 2020-01-01 – 2020-12-31: -87024000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 8201000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Talis Biomedical Corporation · 2020-12-31 Talis Biomedical Corporation (edgar:1584751) Free cash flow: -95225000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-08T15:32:14Z Snapshot: 76359e99ea5544dae0b145f58c9198a64d6485e398959fd41d681c608509871d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1584751?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -87024000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017022003779/tlis-20211231.htm#1854615 Filing: 000095017022003779 Input fundies:CapitalExpenditure: 8201000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017022003779/tlis-20211231.htm#1862023 Filing: 000095017022003779 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 192.04 million Exact value Exact value: -192036000 USD 2021-01-01 – 2021-12-31: -192036000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Talis Biomedical Corporation · 2021-12-31 Talis Biomedical Corporation (edgar:1584751) Net Income: -192036000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-08T15:32:14Z Snapshot: 76359e99ea5544dae0b145f58c9198a64d6485e398959fd41d681c608509871d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1584751/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -192036000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017023009197/tlis-20221231.htm#2687416 Filing: 000095017023009197 The citation records this snapshot. The page link may show a newer release later.	−USD 171.38 million Exact value Exact value: -171384000 USD 2021-01-01 – 2021-12-31: -171384000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Talis Biomedical Corporation · 2021-12-31 Talis Biomedical Corporation (edgar:1584751) Operating Cash Flow: -171384000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-08T15:32:14Z Snapshot: 76359e99ea5544dae0b145f58c9198a64d6485e398959fd41d681c608509871d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1584751/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -171384000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017023009197/tlis-20221231.htm#1801369 Filing: 000095017023009197 The citation records this snapshot. The page link may show a newer release later.	USD 2.87 million Exact value Exact value: 2866000 USD 2021-01-01 – 2021-12-31: 2866000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Talis Biomedical Corporation · 2021-12-31 Talis Biomedical Corporation (edgar:1584751) Capital Expenditure: 2866000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-08T15:32:14Z Snapshot: 76359e99ea5544dae0b145f58c9198a64d6485e398959fd41d681c608509871d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1584751/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2866000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017023009197/tlis-20221231.htm#1809514 Filing: 000095017023009197 The citation records this snapshot. The page link may show a newer release later.	−USD 174.25 million Calculation and evidence -171384000 − 2866000 USD Exact free cash flow: -174250000 USD 2021-01-01 – 2021-12-31: -171384000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 2866000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Talis Biomedical Corporation · 2021-12-31 Talis Biomedical Corporation (edgar:1584751) Free cash flow: -174250000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-08T15:32:14Z Snapshot: 76359e99ea5544dae0b145f58c9198a64d6485e398959fd41d681c608509871d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1584751?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -171384000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017023009197/tlis-20221231.htm#1801369 Filing: 000095017023009197 Input fundies:CapitalExpenditure: 2866000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017023009197/tlis-20221231.htm#1809514 Filing: 000095017023009197 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 113.01 million Exact value Exact value: -113012000 USD 2022-01-01 – 2022-12-31: -113012000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Talis Biomedical Corporation · 2022-12-31 Talis Biomedical Corporation (edgar:1584751) Net Income: -113012000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-08T15:32:14Z Snapshot: 76359e99ea5544dae0b145f58c9198a64d6485e398959fd41d681c608509871d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1584751/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -113012000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017024037648/tlis-20231231.htm#1848040 Filing: 000095017024037648 The citation records this snapshot. The page link may show a newer release later.	−USD 100.14 million Exact value Exact value: -100136000 USD 2022-01-01 – 2022-12-31: -100136000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Talis Biomedical Corporation · 2022-12-31 Talis Biomedical Corporation (edgar:1584751) Operating Cash Flow: -100136000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-08T15:32:14Z Snapshot: 76359e99ea5544dae0b145f58c9198a64d6485e398959fd41d681c608509871d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1584751/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -100136000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017024037648/tlis-20231231.htm#1256011 Filing: 000095017024037648 The citation records this snapshot. The page link may show a newer release later.	USD 1.62 million Exact value Exact value: 1615000 USD 2022-01-01 – 2022-12-31: 1615000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Talis Biomedical Corporation · 2022-12-31 Talis Biomedical Corporation (edgar:1584751) Capital Expenditure: 1615000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-08T15:32:14Z Snapshot: 76359e99ea5544dae0b145f58c9198a64d6485e398959fd41d681c608509871d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1584751/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1615000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017024037648/tlis-20231231.htm#1261062 Filing: 000095017024037648 The citation records this snapshot. The page link may show a newer release later.	−USD 101.75 million Calculation and evidence -100136000 − 1615000 USD Exact free cash flow: -101751000 USD 2022-01-01 – 2022-12-31: -100136000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 1615000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Talis Biomedical Corporation · 2022-12-31 Talis Biomedical Corporation (edgar:1584751) Free cash flow: -101751000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-08T15:32:14Z Snapshot: 76359e99ea5544dae0b145f58c9198a64d6485e398959fd41d681c608509871d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1584751?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -100136000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017024037648/tlis-20231231.htm#1256011 Filing: 000095017024037648 Input fundies:CapitalExpenditure: 1615000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017024037648/tlis-20231231.htm#1261062 Filing: 000095017024037648 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 62.01 million Exact value Exact value: -62007000 USD 2023-01-01 – 2023-12-31: -62007000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Talis Biomedical Corporation · 2023-12-31 Talis Biomedical Corporation (edgar:1584751) Net Income: -62007000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-08T15:32:14Z Snapshot: 76359e99ea5544dae0b145f58c9198a64d6485e398959fd41d681c608509871d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1584751/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -62007000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017024037648/tlis-20231231.htm#1846739 Filing: 000095017024037648 The citation records this snapshot. The page link may show a newer release later.	−USD 53.24 million Exact value Exact value: -53240000 USD 2023-01-01 – 2023-12-31: -53240000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Talis Biomedical Corporation · 2023-12-31 Talis Biomedical Corporation (edgar:1584751) Operating Cash Flow: -53240000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-08T15:32:14Z Snapshot: 76359e99ea5544dae0b145f58c9198a64d6485e398959fd41d681c608509871d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1584751/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -53240000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017024037648/tlis-20231231.htm#1254568 Filing: 000095017024037648 The citation records this snapshot. The page link may show a newer release later.	USD 486,000 Exact value Exact value: 486000 USD 2023-01-01 – 2023-12-31: 486000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Talis Biomedical Corporation · 2023-12-31 Talis Biomedical Corporation (edgar:1584751) Capital Expenditure: 486000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-08T15:32:14Z Snapshot: 76359e99ea5544dae0b145f58c9198a64d6485e398959fd41d681c608509871d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1584751/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 486000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017024037648/tlis-20231231.htm#1259640 Filing: 000095017024037648 The citation records this snapshot. The page link may show a newer release later.	−USD 53.73 million Calculation and evidence -53240000 − 486000 USD Exact free cash flow: -53726000 USD 2023-01-01 – 2023-12-31: -53240000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 486000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Talis Biomedical Corporation · 2023-12-31 Talis Biomedical Corporation (edgar:1584751) Free cash flow: -53726000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-08T15:32:14Z Snapshot: 76359e99ea5544dae0b145f58c9198a64d6485e398959fd41d681c608509871d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1584751?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -53240000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017024037648/tlis-20231231.htm#1254568 Filing: 000095017024037648 Input fundies:CapitalExpenditure: 486000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1584751/000095017024037648/tlis-20231231.htm#1259640 Filing: 000095017024037648 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

18 filings · 992 latest values · 992 originally reported values

Dataset published 2026-11-08. Source filing dates and reporting periods are shown separately.

Identifiers: 0001584751, 1584751, TLIS, edgar:1584751

Also known as SlipChip Corp, Talis Biomedical Corp, Talis Biomedical Corporation

Talis Biomedical Corporation

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2023 2023-01-01 – 2023-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation